Effectiveness of Sulfasalazine Therapy Following Mesalazine Treatment Failure in Children with Ulcerative Colitis Authors: Paola Ruška, Ines Doder, Ana Močić Pavić, Zrinjka Mišak, Sanja Kolaček, Iva Hojsak Published: 2026 ABSTRACT PurposeThis study aimed to assess the effectiveness of sulfasalazine therapy in children with ulcerative colitis (UC) after mesalazine treatment failure and to compare its effectiveness with that of mesalazine and azathioprine used after the first relapse.MethodsData from all children newly diagnosed with UC between January 2010 and December 2021 who had at least 12 months of follow-up were retrospectively analyzed.ResultsOf 189 children newly diagnosed with UC, 99 (52.4%) were treated with mesalazine alone, experienced a relapse, and were included in the study. The mean age was 12.8 years (standard deviation, 0.45), and 56 patients (56.6%) were male. After relapse, 35 children (35.4%) switched to sulfasalazine. Sulfasalazine treatment was effective in 28 patients (80.0%), and 19 patients (54.3%) remained relapse-free at 12 months. Patients who switched to sulfasalazine had more extensive disease and a higher Pediatric Ulcerative Colitis Activity Index than those who continued mesalamine treatment, but both disease extent and the index were lower than in patients who received azathioprine. Relapse-free survival did not differ among mesalazine, sulfasalazine, and azathioprine treatments (p=0.182).ConclusionSwitching from mesalazine to sulfasalazine may be a viable therapeutic option for carefully selected children with mild to moderate UC, even after mesalazine treatment failure. INTRODUCTION Treatment of children with ulcerative colitis (UC) includes medical and surgical management [1]. The main medication groups include 5-aminosalicylic acid (5-ASA), steroids, immunomodulators, and biologics, whereas colectomy is a treatment option for patients with severe disease or disease refractory to conventional therapy. According to the guidelines of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Crohn´s and Colitis Organization (ECCO), 5-ASA medications are first-line treatments for both induction and maintenance therapy in mild to moderate UC [1]. Before the development of 5-ASA medications, sulfasalazine was the primary drug used to manage UC. Sulfasalazine consists of two main components: the antibiotic sulfapyridine and 5-ASA [2]. In the 1970s, scientists discovered that the 5-ASA component was responsible for the therapeutic effect of sulfasalazine, prompting the development of 5-ASA compounds [3]. In contrast, the sulfapyridine component was considered responsible for the adverse effects of sulfasalazine [4], leading to the development of compounds containing only 5-ASA, such as mesalazine, olsalazine, and balsalazide. Studies have shown that mesalazine induces remission in 35% to 55% of pediatric patients [56]. Comparisons of the efficacy of mesalazine and sulfasalazine are available but scarce [78]. To our knowledge, no pediatric studies have evaluated the efficacy of sulfasalazine after mesalazine treatment failure, and studies in adults are also limited. Therefore, this study aimed to assess the effectiveness of sulfasalazine in children with UC after mesalazine treatment failure and to compare it with mesalazine and azathioprine treatments used after the first relapse. MATERIALS AND METHODS We retrospectively analyzed data from all children newly diagnosed with UC at Children’s Hospital Zagreb between January 2nd, 2010, and December 31st, 2021, who had at least 12 months of follow-up. The following data were included: demographic characteristics; disease location; laboratory findings (hemoglobin, C-reactive protein (CRP), albumin, and calprotectin), Pediatric Ulcerative Colitis Activity Index (PUCAI) scores at diagnosis, at the onset of each relapse, and at the end of follow-up; treatment type at diagnosis, before each relapse, and at the end of follow-up; number of relapses, if any; duration of remission; and treatment types used for remission induction and maintenance. UC was diagnosed according to the revised Porto criteria, and disease location was classified according to the Paris classification [9]. Although treatment was determined at the discretion of the attending physician, the principles of the ESPGHAN/ECCO guidelines for UC treatment were followed whenever possible [1]. Patients eligible for this study were those who experienced a relapse while receiving mesalazine monotherapy and who continued mesalazine or switched to sulfasalazine or azathioprine for maintenance therapy after relapse. For patients who continued mesalazine, the dose was either adjusted or local mesalazine therapy was added after relapse. Patients with sclerosing cholangitis and those treated from diagnosis with only local (topical) mesalazine, sulfasalazine, azathioprine, or biologic therapy were excluded from the study. Remission and disease activity were defined using the PUCAI score. Relapse was classified as mild when the PUCAI score was 10–34, moderate when it was 35–64, and severe when it was 65 or higher; remission was defined as a PUCAI score below 10 [10]. In addition to a PUCAI score below 10 and complete absence of symptoms, remission required normal laboratory findings, including calprotectin, and no need for corticosteroid therapy. Induction treatment was considered successful only if symptoms completely resolved within 2 or 3 weeks. Maintenance treatment was considered successful if the patient remained symptom-free for at least 1 month after withdrawal of induction therapy, provided the induction and maintenance therapies differed. The study was approved by the Ethics Committee of Children's Hospital Zagreb. The primary outcome was the effectiveness of sulfasalazine in achieving remission in children after mesalazine treatment failure. The secondary aim was to compare the effectiveness of sulfasalazine with that of mesalazine or azathioprine after the first relapse. Statistical analysis The Shapiro-Wilk test was used to assess data distribution. Differences between categorical variables were assessed using the chi-square test. Differences in continuous variables were assessed using parametric ANOVA. Binary logistic regression was used to assess possible risk factors for a second relapse. A p-values <0.05 were considered statistically significant. Survival analysis was performed using Kaplan-Meier curves. Statistical analyses were performed using the IBM SPSS Statistics for Windows, Version 26.0 (IBM Co). RESULTS During the study period, 189 children newly diagnosed with UC were identified, of whom 122 (64.6%) received mesalazine alone. Overall, 99 (81.1%) of these 122 patients experienced a relapse during the observation period and were eligible for the study. The mean age of the included patients was 12.8 years (standard deviation [SD], 0.45), and 56 patients (56.6%) were male. Corticosteroids were used for remission induction in 51 patients (51.5%), mesalazine alone in 31 patients (31.3%), including 26 who also received local mesalazine therapy, and sulfasalazine alone in 17 patients (17.2%). Among patients who received sulfasalazine alone for remission induction, 16 (94.1%) achieved remission. For remission maintenance, mesalazine alone was used in 41 patients (41.4%), including 26 who also received local mesalazine therapy; sulfasalazine was introduced as maintenance treatment in 35 patients (35.4%); and 23 patients (23.2%) received azathioprine. Azathioprine was used in combination with mesalazine in 18 patients (78.3%) and with sulfasalazine in 3 patients (13.0%). Among the 35 patients treated with sulfasalazine, treatment was effective in 28 (80.0%). At 6 and 12 months, 27 (77.1%) and 19 (54.3%) patients, respectively, were in remission. Overall, 23 patients (65.7%) experienced a relapse after a mean of 15.4 months (SD, 11), and the mean follow-up duration was 38.8 months (SD, 24). Differences among patients treated with mesalazine, sulfasalazine, and azathioprine after relapse are presented in Table 1. Patients in whom sulfasalazine was introduced had more extensive disease and were more likely to have moderate disease based on the PUCAI score than patients in the mesalazine group, whereas the azathioprine group had the highest proportions of moderate and severe disease. Hemoglobin levels were lower in the sulfasalazine group and lowest in the azathioprine group. Table 1Differences in laboratory and clinical parameters among the treatment groupsParameterMesalazine (n=41)Sulfasalazine (n=35)Azathioprine (n=23) p-valueAge (yr)12.3 (4.4)13.1 (3.9)12.5 (3.5)0.69Male23 (56.1)24 (68.6)9 (39.1)0.086BMI z score−0.08 (1.2)−0.25 (0.9)−0.6 (1.6)0.256Disease location0.009E15 (12.2)0 (0.0)0 (0.0)E26 (14.6)1 (2.9)8 (34.8)E36 (14.6)8 (22.9)5 (21.7)E424 (58.5)26 (74.3)10 (43.5)Disease duration before relapse (mo)11.3 (12.4)9.8 (12.2)6.5 (5.9)0.609Disease activity* at relapse<0.001Mild35 (85.4)22 (62.9)5 (21.7)Moderate6 (14.6)13 (37.1)17 (73.9)Severe0 (0.0)0 (0.0)1 (4.3)Hemoglobin levels at treatment initiation (g/L)127 (13.9)120.9 (21.7)113 (19.5)0.024† CRP at treatment initiation (mg/L)20.3 (44)17.3 (29)29.3 (45)0.455Albumin at treatment initiation (g/L)43.3 (4.3)41.7 (3.3)39.5 (5.3)0.062† Calprotectin at treatment initiation (mg/g)1,195 (820)1,857 (1,047)18,189 (3,288)0.046Concomitant corticosteroid use11 (26.8)17 (48.6)23 (100.0)<0.001Local mesalazine therapy26 (63.4)12 (34.3)11 (47.8)0.04Remission 12 mo after treatment initiation27 (65.9)19 (54.3)16 (69.6)0.428Remission duration (mo)28.6 (25)18.6 (18)22.4 (16.2)0.111Relapse after treatment initiation25 (61.0)23 (65.7)15 (65.2)0.898Values are presented as mean (standard deviation) or number (%).BMI: body mass index, CRP: C-reactive protein.*Based on Pediatric Ulcerative Colitis Activity Index.†Post hoc analysis: significant for the mesalamine vs. azathioprine groups. Differences in laboratory and clinical parameters among the treatment groups Values are presented as mean (standard deviation) or number (%). BMI: body mass index, CRP: C-reactive protein. *Based on Pediatric Ulcerative Colitis Activity Index. †Post hoc analysis: significant for the mesalamine vs. azathioprine groups. Relapse-free survival did not differ among mesalazine, sulfasalazine, and azathioprine treatments (p=0.182) (Fig. 1). Kaplan-Meier curves showing cumulative relapse-free survival among patients treated with mesalazine (blue curve), sulfasalazine (red curve), and azathioprine (green curve). None of the potential risk factors, including sex, age, time to first relapse, disease extent, concomitant corticosteroid use, and maintenance treatment, significantly predicted a second relapse (Fig. 2). Results of the univariable binary regression model for predicting a second relapse. DISCUSSION Our study showed that a substantial proportion of patients (80.0%) achieved remission with sulfasalazine after mesalazine treatment failure. Moreover, 54% of patients remained in remission 12 months after sulfasalazine initiation and therefore did not require immunosuppressive treatment. As noted above, no pediatric data are available on the effect of sulfasalazine treatment after mesalazine failure. Adult data are also limited to three studies [41112]. Yoshino et al. [4] reported that 69% of patients who failed mesalazine therapy achieved clinical remission after initiating sulfasalazine. The other two studies reported similar findings regarding the effectiveness of switching to sulfasalazine: 59% and 67% of patients responded, respectively [1112]. Our findings in the pediatric population are similar. Given the findings and the fact that both medications contain a 5-ASA component, it is reasonable to consider why sulfasalazine can successfully induce remission after mesalazine treatment. This mechanism has not yet been elucidated, but several explanations are possible. First, sulfasalazine delivers more 5-ASA to the colon [13]. Previous research has shown that only a small proportion of sulfasalazine is absorbed in the small intestine and that approximately 70% of the drug reaches the colon unchanged [13]. In contrast, approximately 80% of mesalazine is absorbed in the small intestine, leaving only 20% to reach the colon [14]. Second, as noted above, sulfapyridine may reduce the concentration of pro-inflammatory intestinal bacteria [7]. Thus, sulfapyridine may act as an additional active substance alongside 5-ASA. These potential advantages may suggest that sulfasalazine is more effective than mesalazine. However, this study was not designed to address this question because sulfasalazine was used almost exclusively as second-line 5-ASA therapy. In this context, two meta-analyses compared the efficacy of mesalazine and sulfasalazine [78]. Nikfar et al. [7] found no significant differences in the relative risks of overall improvement (p=0.63) or relapse (p=0.85) between the two treatment options. In contrast, a more recent meta-analysis [8] showed that sulfasalazine was significantly superior to other 5-ASA medications for maintaining remission (p=0.01). The meta-analysis included 12 studies involving 1,655 patients. The minimum treatment duration in the included studies was 6 months. Importantly, the studies did not compare sulfasalazine exclusively with mesalazine; they also included other 5-ASA medications. We found no pediatric data comparing mesalazine and sulfasalazine therapies. The only pediatric study comparing sulfasalazine with a 5-ASA medication was conducted by Ferry et al. [15] in 1993. This randomized, double-blind study compared olsalazine and sulfasalazine in 56 patients. At the end of follow-up, 39% of patients receiving olsalazine had improved, compared with 79% of those receiving sulfasalazine (p=0.006). In our study, sulfasalazine was evaluated as second-line treatment after mesalazine failure in patients who otherwise might have received azathioprine. Sulfasalazine was effective in 80% of patients; 77% were in remission after 6 months and 54% after 1 year. The 12-month remission rate was slightly lower than the rates in the other two groups, comprising patients who continued mesalazine and those in whom azathioprine was introduced, although the difference was not statistically significant. However, several factors should be considered when interpreting these results. The mesalazine group had milder relapses, required fewer corticosteroids for remission induction, and had less extensive disease. In contrast, patients in whom azathioprine was added had the most severe disease, and all required corticosteroids. Because this was not a randomized trial and the sample size was small, no firm conclusions can be drawn; nevertheless, appropriate patient selection appears to be particularly important. Ultimately, oral mesalazine may be better tolerated than sulfasalazine (relative risk of adverse effects, 0.48; 95% CI, 0.36–0.63); therefore, 5-ASA medications are recommended as first-line therapy [11516]. Current guidelines do not mention sulfasalazine use in patients after mesalazine treatment failure, which is likely the most important contribution of this manuscript to the literature. This study has several limitations, mainly its retrospective design, the relatively small number of children receiving sulfasalazine, and the absence of uniform inclusion criteria. Furthermore, routine endoscopy was not performed in many patients; therefore, mucosal healing could not be assessed. However, to our knowledge, this is the first study to evaluate the efficacy of sulfasalazine in children with UC after mesalazine treatment failure. Switching from mesalazine to sulfasalazine may be a viable therapeutic option for children with mild to moderate UC, even after mesalazine treatment failure. Other therapeutic options (immunomodulatory drugs, biologic treatment, and surgery) are more expensive and more complex for patients and carry a risk of more serious adverse effects, as shown in previous studies [1718]. Nevertheless, appropriate patient selection is essential.